About Foresight Diagnostics
Foresight Diagnostics is a company based in Aurora (United States) founded in 2020 by Ash Alizadeh, David Kurtz, Jake Chabon, and Maximilian Diehn was acquired by Natera in December 2025. Foresight Diagnostics has raised $104.25 million across 3 funding rounds from investors including Natera, Pear VC and Foresite Capital. Foresight Diagnostics operates in a competitive market with competitors including Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
- Headquarter Aurora, United States
- Founders Ash Alizadeh, David Kurtz, Jake Chabon, Maximilian Diehn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Foresight Diagnostics
Unlock access to complete
Unlock access to complete
Funding Insights of Foresight Diagnostics
Foresight Diagnostics has successfully raised a total of $104.25M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $33 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Foresight Diagnostics
Foresight Diagnostics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Natera, Pear VC and Foresite Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked | |
|
Venture capital is provided to health tech and biology innovations.
|
Locked | Locked | Locked | |
|
Bluebird Ventures is engaged in life sciences venture capital investment.
|
Locked | Locked | Locked |
Investor details for Foresight Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Foresight Diagnostics
Investment portfolio details for Foresight Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Foresight Diagnostics
Detailed financials for Foresight Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Foresight Diagnostics Comparisons
Peer comparison for Foresight Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Foresight Diagnostics
Foresight Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Foresight Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Foresight Diagnostics
Complete news archive for Foresight Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Foresight Diagnostics
Foresight Diagnostics was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Foresight Diagnostics is headquartered in Aurora, United States. It is registered at Aurora, Colorado, United States.
Jake Chabon is the current CEO of Foresight Diagnostics. They have also founded this company.
Foresight Diagnostics is a funded company, having raised a total of $104.25M across 3 funding rounds to date.
Foresight Diagnostics was founded in 2020 and is based in Aurora, United States. A liquid biopsy testing platform is developed using PhasED-Seq technology to detect ctDNA levels in patients with solid tumors and hematologic malignancies. Operations focus on minimally invasive diagnostics within the biotechnology sector, enabling early cancer detection through non-invasive methods. The platform supports clinical applications for tumor monitoring and treatment response assessment.
Foresight Diagnostics's top competitors include Guardant Health, GRAIL and Foundation Medicine.
Foresight Diagnostics has 8 investors. Key investors include Natera, Pear VC, Foresite Capital, Civilization Ventures, and Bluebird Ventures.